The conception and creation of scientific posters for the pharmaceutical industry is a demanding task that requires the highest levels of professionalism and great technical knowledge. The Cinnamon Agency understands this only too well, having had a wealth of experience working with some of the industry’s major pharmaceutical brands at conferences and events throughout the world.
The Cinnamon Agency, working in conjunction with Adelphi Communications, recently produced 4 scientific posters and conference handouts for our client Genentech, a subsidiary of Roche Pharmaceuticals based in America, for the European League against Rheumatism (EULAR) Conference on 25/28 May, 2011, at ExCel in London. Genentech is a leading pharmaceutical research company, delivering new treatment options to patients with serious or life-threatening medical conditions such as advanced rheumatoid arthritis, and is one of the world’s leading producers of autoimmune disease therapies, like Rituxan. Genentech works in conjunction with clinicians, healthcare professionals and patients to offer new hope to sufferers, by developing biopharmaceutical products that pave the way for new treatments that can impede the progression of autoimmune diseases and prevent joint damage and pain.
Our brief was to produce 4 scientific posters and handouts for our client, Genentech, to draw attention and focus to the new, innovative research work they were doing in the autoimmune disease field. The aims of EULAR, which meets annually, is to reduce the burden of rheumatic diseases on individuals and on society and improve the treatment, the prevention and the rehabilitation of musculoskeletal diseases. It does this by supporting education and research projects in the field of rheumatology and funding collaborative research between rheumatology groups in Europe and across the Atlantic.
There is no cure for rheumatoid arthritis, so researchers at Genentech and Roche Pharmaceuticals are looking at innovative ways to deepen their understanding of the auto-immune system and pinpoint the causes and course of arthritis. Their discoveries have already resulted in new drugs offering real patient benefits. Biopharmaceutical therapies like Rituxan selectively intervene in the molecular course of the disease without weakening the immune system as a whole. This new mechanism of action alleviates pain and holds the disease in check.
Currently doctors rely on a constellation of signs and symptoms to make a firm diagnosis of rheumatoid arthritis. By that time, many patients are already disabled by their damaged joints. Genentech’s goal is earlier detection, using a reliable disease indicator in the form of a biomarker, incorporated in a diagnostic test. Only then will doctors be able to intervene early enough to prevent joint damage and disability.